Stock analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The stock has a 50-day moving average of $0.14. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks Leading the U.S. Agriculture Comeback
- Are Penny Stocks a Good Fit for Your Portfolio?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How Investors Can Find the Best Cheap Dividend Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.